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Abstract
Aims:To evaluate the early cancer control rates, morbidity and mortality in men undergoing
radical retropubic prostatectomy (RRP) for clinically localized adenocarcinoma prostate.
Methods:Patient’s characteristics, operative data, progressive-free survival rates, morbidity
and mortality were analyzed for 23 men with clinical T1-2 prostate cancer who underwent
surgery with an intent to treat by RRP between December 1997 to July 2001.
Results:Patient’s mean age was 63±6.2 years (range 51 to 76 years) with American Society
of Anesthesiology (ASA) status I in 4%, II in 65% and Ill in 31%. Two third of the patients
had lower urinary tract obstructive symptoms, followed by hematuria (9%) and back pain
(4%). Clinical stages were Tib in 4%, Tic in 9%, T2a in 17%, T2b in 22% and T2c in 48% of
the patients. Mean pre-operative serum prostate specific antigen (PSA) was 25 ±29 ng/ml
(1.110 99.3). Bilateral pelvic lymphnode disection(PLND) and RRP was performed in 20
cases (nerve-sparing RRP 5 cases). In 3 cases with gross lymph node metastasis at frozen
section, only bilateral orchidectomy was done. The mean operative time was 270 ±65
minutes and mean blood loss was 1097 ±654 mIs. Packed cell transfusions were nil in 26%,
1-2 units in 44%, 3-4 units in 26% and 5 units in 4% of the patients who underwent RRP.
The mean length of hospital stay was 10.2 ± 1 days. Out of 20 patients who underwent RRP,
65% of tumors were confined to the specimen, 20% had seminal vesicle invasion and 15%
had nodal metastasis. There was no pen-operative mortality while 2 patients developed
epididymo-orchitis and I had myocardial ischemia (without infarction). Overall 87% of the
patients were fully continent and 13% had mild to moderate stress urinary incontinence. The
mean time of return of continence was 11.5 ± 11.6 weeks. Two of the 3 patients (66%) with
follow up information and having undergone nerve-sparing RRP are potent.
At a mean follow up of 19.4 ± 13 months (range 3-45 months), 20 of 23 total patients (87%)
and 17 of 20 RRP patients (85%) remained free of disease recurrence with PSA 0.4 ng/ml.
Conclusion:Our early results confirm the excellent potential for cancer control and low
morbidity of radical prostatectomy for men with localized prostate cancer. These results are
in conformity with the vast Western experience. Long-term results will be provided (JPMA
52:200; 2002).
Introduction
Three to four decades ago, prostate cancer ranked low as a cause of morbidity and mortality
for the Western males1-3. Today, it represents the most commonly diagnosed related death4. It
is estimated that during the year 2001, it would account for 31% of newly diagnosed cancers

and 11% of cancer-related deaths in American men4.
This dramatic increase in the disease burden has been attributed to availability of refined
methods of diagnosis (regular digital rectal examination, prostate specific antigen blood test,
transrectal ultrasound, systematic prostatic biopsy), increased life expectancy with an ever
aging population, as well as, to enhanced awareness about the disease in Western
community5,6.
The disease burden however, remains remarkably different between the Eastern and the
Western countries7. The age-adjusted prostate cancer mortality rates from China, Japan and
other Eastern countries appears less threatening than those reported from Europe and USA4.
While the exact reasons remain unclear, genetic, environmental and dietary factors have been
implicated8. Interestingly despite widely variable incidence of clinically detectable cases
between different populations, autopsy studies from around the world show no variation in
the prevalence of small latent cancers in men who die with no clinical evidence of prostate
cancer9-13.
Recent data from some of the Asian countries indicates a rapid increase in the incidence and
mortality of prostate cancer14-16. Between 1985 and 1997, a 230% increase in prostate cancer
mortality has been observed in Japanese men14. This change resembles the earlier trends of
Western countries and is attributed to an aging population, environmental! dietary factors and
better diagnostic methods. Since mortality from prostate cancer increases more rapidly with
age than any other cancer and life expectancy in Asian men, like those in the west, is
increasing, the incidence and mortality from prostate cancer is likely to increase significantly
over time17,18. Thus, if prostate cancer is likely to become a major health problem for Asian
men it is highly desirable that appropriate measures be undertaken to diagnose and manage
this disease effectively.
While the optimal treatment of prostatic cancer is debatable, radical prostatectomy has
evolved as an established method to treat clinically localized prostate cancer in appropriately
selected men. The major advantage of radical surgery is the high probability that the cancer
can be completely removed, especially if it is confined to the prostate pathologically19.
Fifteen-year cancer specific survival rates range from 86% to 93%20. With refmements in
surgical technique and improved perioperative care, the morbidity of the operation has
markedly decreased and the 30-day mortality in contemporary literature is less than 0.3%20,21
Similarly, blood transfusion rates, mean hospital stay and cost of care has also decreased20,21.
The main long-term complications relate to potency and continence. While significant
urinary incontinence and anastamotic strictures are infrequent, post-operative erectile
dysfunction still remains as a major morbidity of this operation.
There is limited Asian data on surgical treatment for localized prostate cancer22-24. We,
herein, present our early results of radical retropubic prostatectomy from a single institution
in men with clinical stages Ti to T2 prostate cancer.
Patients and Methods
Between December 1997 and June 2001, 23 men with clinical stage TI-2NxMo prostatic
adenocarcinoma underwent PLND with or without RRP at The Aga Khan University
Hospital. Clinical stages were assigned preoperatively using the TNM system. In addition to
routine evaluation, all patients had digital rectal examination (DRE) and serum prostate
specific antigen (PSA) estimation, (Abbott Laboratories, Chicago, IL, IMX assay) whilst

most had transrectal ultrasonography (TRUS) prior to surgery. Patients with clinical
suspicion of extraprostatic extension of cancer (T3 lesions) were not considered for radical
prostatectomy. The PSA levels were obtained prior to DRE or manipulation or at least 3
weeks after a prostatic biopsy or manipulation. A PSA level of 4.0 ng!ml or more was
considered an abnormal result and the results obtained closest to the surgery were used as
preoperative PSA values. Distant metastases were excluded by a normal radionuclide bone
scan and a CT scan of the abdomen and pelvis.
Standard pelvic lymph node dissection and modified anatomical radical retropubic
prostatectomy was performed21. We routinely perform frozen section analysis of the pelvic
lymph nodes and those who had gross metastasis did not undergo radical prostatectomy,
instead bilateral orchidectomy was carried out. In patients who were potent preoperatively,
nerve-sparing radical prostatectomy was performed when neurovascular bundles were
intraoperatively assessed to be grossly uninvolved by cancer. In patients with palpable tumor
in close proximity of neurovascular bundle, the ipsilateral bundle was excised. Details of the
operative findings, surgical procedure, intra and post-operative complications, blood loss and
transfusions were recorded. Patients were discharged with indwelling Silicone catheter to be
removed at 2 weeks in the outpatient clinic.
All prostatic biopsy specimen, whether obtained at our university or outside, were reviewed
at our pathology department to confirm the presence of malignancy. The radical
prostatectomy specimens were fixed en bloc in formaldehyde and painted on the outside with
India ink, then sectioned. The histological grades (Gleason’s primary and secondary grades)
were recorded and the presence of seminal vesicle invasion, lymph nodes metastasis and
tumor extension outside the surgical specimen was noted. All lymph nodes were examined
for metastasis. Based on these findings, the pathologic stage was assigned according to the
TNM system.
Following initial postoperative visits, the patients were followed with DRE and serum PSA
levels, more or less, every 3 months for 1 year and subsequently every 6 months. Progression
of the disease was defined as either clinical evidence of disease recurrence or biochemical
recurrence with progressively rising PSA, with levels >0.4 ng/ml. At each visit, urinary
continence, potency, development of any complication and additional treatments undertaken
were noted.
Results
The mean age was 63 ± 6.2 years (median 64 years, range 51 - 76). ASA classification
showed that 4% of the patients belonged to class I, 65% to class II and 31% to class III. Most
patients were clinically symptomatic with 10 (44%) presenting with lower urinary tract
obstructive symptoms (Table 1).

Only 40 (17%) of the patients were asymptomatic and were diagnosed with prostate cancer
following routine PSA testing.
On DRE, 3 patients (13%) had normal prostate while 20 (87%) had abnormal findings (Table
2).

This included 4 with a unilateral nodule involving less than half of the lobe (T2a lesion), 5
with a unilateral nodule involving more than half of the lobe (T2b lesion), and 11 with
bilaterally palpable nodules (T2c lesion). Patients with clinical T3 lesions were not
considered for radical surgery.
Serum PSA levels were found to be elevated above normal in all cases except in one patient
who was on hormonal therapy for 2 months following transuretheral resection of prostate
(TURP) done outside. He was taken off the hormonal therapy prior to radical prostatectomy.
The mean PSA was 25 ± 29, (median PSA = 13.7, range 1.1 -99). PSA ranges are given in

Table 2.
All patients had a negative bone scan and CT scan of the abdomen and pelvis for metastatic
disease. In one case with serum PSA of 84 ng/ml, MRI bone survey and trephine bone
marrow biopsy was done and was also negative for metastasis.
Five patients had evidence of nodal metastasis at frozen section. In 3 with gross metastasis
RPR was abandoned and bilateral orchidectomy was carried out. While in 2 who had micro
metastasis, standard RRP and bilateral orchidectomy was performed. The remaining 18
patients with no nodal metastasis underwent standard RRP (Table 3).

The decision to perform nerve-sparing RRP was based on pre-operative potency status and
intra-operative assessment of proximity of the cancer to the neuro-vascular bundles (NVB).
Of 20 cases, who had RRP 5 patients (25%) had complete bilateral NVB preservation and 7
(35%) had partial NVB preservation. In 8 patients (40%) bilateral NVB resection had to be
performed in order to achieve a wide clearance margin.
Table 3 shows the operative time, estimated blood loss, transfusions, and patient’s length of
stay. Overall, 74% of all cases (17 of 23) and 85% of RRP cases (17 of 20) received
perioperative blood transfusion. The mean transfusion requirement was 2.2 ±, 1.5 packed red
cell units per patient. In RRP cases, 15% had no transfusions while 50% received 1 - 2 units,
30% had 3 - 4 units and 5% had 5 units of packed cell transfusions.
There was no mortality. Perioperative complications were observed in 3 patients (13%)
including 1 case (4%) of myocardial ischaemia with no infarction and 2 cases (9%) who
developed epididymo-orchitis.
Overall, 87% patients (20 of 23) are fully continent while 13% have mild to moderate stress
urinary incontinence. Amongst 20 patients who underwent RRP, 85% (17 of 20) are fully
continent and 15% (3 of 20) have mild to moderate stress urinary incontinence at> 6 months
after surgery requiring I to 2 pads per day (Table 4).

The overall pathological staging (TNM) and grading (Gleason grading system) is shown in
Table 5.

At a mean follow up of 19.4 ± 13 months (median 15, range 3 - 45), 20 of 23 total patients
(87%) and 17 of 20 patients who had RRP (85%) remain free of cancer sections revealed
micrometastasis in pelvic lymph nodes.
In patients who underwent RRP and are continent, the mean time to return to fully continent
status was 11.5 ±11.6 weeks (median 8; range 2 - 40 weeks). The return of continence in

patients with previous TURP was 10 ± 2 weeks compared with 12 ±. 13 weeks in those with
no previous prostatic surgery. Three patients (15%) developed anastamotic strictures; 2
underwent optical urethrotomy and one had urethral dilation. The follow up information
about potency status is available in 3 of 5 cases who had bilateral NVB preservations. Two of
these 3 patients (66%) are potent.
recurrence with PSA levels 0.4 ng/ml. This is with no further cancer-related treatment except
for adjuvant external beam radiation therapy in 2 cases administered on the basis of adverse
histopathology. All 3 patients who failed surgical treatment (PSA >0.4ng/ml) had high-grade
cancer with seminal vesicle invasion.
Discussion
Prostate cancer remains an important cause of morbidity and mortality in middle aged and
elderly males. While the disease burden is far more pronounced in the western world4, recent
data indicates a significant increase in the age-adjusted incidence and mortality rates in many
Asian countries14-16. Unfortunately a substantial percentage of Asian men still present with
regionally advanced and metastatic cancer, which remains incurable25. This can be compared
to the earlier pattern of disease in the western world. In the pre-PSA era of the 1970s, only
50% of the cancers detected were clinically organ-confmed (clinical stage A and B,
Whitmore and Jewett Classification), and 25-30% had metastases at diagnosis26,27. The last 3
decades, however, witnessed major refinements in the diagnosis and treatment of prostate
cancer. By utilizing the improved diagnostic techniques of regular DRE, serum PSA,
transrectal ultrasound and systematic biopsies in select cases, over 90% of cancers currently
diagnosed in screening studies are clinically organ-confmed and 70% of those are
pathologically organ confined6,28. Similarly, in non screened populations, 70% of cancers
detected by DRE or PSA are clinically organ-confined (Tl-2,NxMo) and about half of those
treated surgically are pathologically confined to the prostate (pTl-2,NoMo)29. The incidence
of pelvic lymph node metastasis has decreased to 5-7% in recent series of radical
prostatectomy30,31. This demonstrates a remarkable stage migration with an increasing
percentage of localized cancers being diagnosed in younger men, amenable to potentially
curative treatment.
Similarly, marked advancements have taken place in improving the techniques of potentially
curative treatment options of radical prostatectomy and radiation therapy. Reiner and Walsh32
described the anatomical RRP with delineation and control of dorsal venous complex. This
led to marked reduction in intraoperative blood loss, which used to be a major morbidity of
this operation. Subsequently, Walsh and Donker33 defined the anatomy of the cavernosal
nerves and pelvic plexus. With nerve-sparing operation34, it has become possible to preserve
sexual function in a substantial percentage of appropriately selected patients without
compromising cancer control. A much improved understanding of the anatomy of striated
urethral sphincter has also led to modifications in surgical technique with subsequent
reduction in the frequency of postoperative urinary incontinence.35
The major advantage of surgery in the treatment of clinically localized prostate cancer is the
high probability that the cancer would be completely removed, especially if it is confined
within the prostate pathologically19,36. In modern series, 80% of patients with clinical stage
Tl-2, NxMo prostate cancer treated with radical prostatectomy have no evidence of
progression at 5 years as assessed by PSA estimation and 70% are free of progression at 10

years21. Radical surgery, however, has its associated morbidity and mortality though
markedly decreased than before. Postoperative mortality is rare, accounting for 0.2% to 0.7%
in large contemporary series. Serious morbidity (myocardial infarction, pulmonary
embolism, pneumonia) occurs in 2 to 3% and the need for a blood transfusion is in about
10% cases37. Therefore, the risk-benefit analysis is crucial while formulating treatment plan
for an individual patient with prostate cancer.
Radical prostatectomy should be considered for men with clinically localized prostate cancer
if they are in good general health and have a life expectancy of 10 years or longer. The risk
of spread of cancer with conservative treatment needs to be assessed against the potential
side effects of radical surgery. Thus, the most important factors’ that influence the riskbenefit analysis include the age and general health of the patient, the extent of cancer
involvement (PSA, grade, stage) and the potential of cure and complications with surgical
treatment20.
Our small series confirms the excellent cancer control potential of this operation, although
the patients need a longer follow-up. The effective management of prostate cancer in a
developing country, however, remains far from acceptable. For a variety of reasons, there are
no concerted efforts to diagnose this cancer at an earlier stage. Thus, most patients in
Pakistan still present with locally advanced or metastatic cancer and cannot be considered for
curative treatment. Even, in our select group of Ti -2 cancer cases, most patients had a
significant disease burden with bilateral prostatic nodularity (cT2c stage) present in 48% of
cases. Only 9% of the cases in our series were Tic cancers, (elevated PSA and normal DRE).
This contrasts remarkably with the western series where Tic cancers account for upto half of
all treated cases.19,34,36 In our early experience, the blood transfusion rate and the length of
stay is higher than the contemporary series, 19,34,36 which hopeflully would improve with
increasing experience. Our cancer control rate, return of urinary continence and potency data
compares favorable with the contemporary data.19,34,36,37 A higher than expected percentage
of our patients developed anastomotic strictures, which could be related to previous TURP in
one of three such cases. Despite most cases having an ASA II and III status, we fortunately
did not encounter any serious complications or perioperative mortality.
In conclusion, radical prostatectomy appears to be generally safe and can effectively
eradicate cancer in a large proportion of patients. With refinements in surgical technique and
improved anesthesia facilities, the surgery related morbidity and mortality has markedly
decreased. We recommend radical prostatectomy as a potentially curative option in select
men with localized prostate cancer.
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